14 completed, 4 terminated, 4 unknown, 2 enrolling by invitation. 10 Phase 3, 6 Phase 2, 4 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 5, Terminated 4, Active not recruiting 1 |
| Phase 2 | 6 | Completed 4, Not yet recruiting 1, Recruiting 1 |
| Phase 4 | 4 | Enrolling by invitation 2, Unknown 2 |
| Phase 1 | 1 | Completed 1 |
Follow Eosinophilic Asthma: new trials by email Literature Review of Eosinophilic Asthma trials Research Report on Eosinophilic Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fasenra: An Asthma Study Budesonide-albuterol, Benralizumab - Eosinophilic Asthma, Severe Asthma | Phase 4 | Enrolling by invitation | Endeavor Health | 40 | 2026-07-01 | 2026-09-15 |
| A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma KT-621, Placebo - Eosinophilic Asthma | Phase 2 | Recruiting | Kymera Therapeutics, Inc. | 264 | 2026-01-28 | 2026-10-06 |
| A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma AD17002, Formulation buffer - Eosinophilic Asthma | Phase 2 | Not yet recruiting | Advagene Biopharma Co. Ltd. | 126 | 2025-12-01 | 2025-11-26 |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| Eosinophil Subpopulations in Eosinophilic-associated Diseases Eosinophilic Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Not yet recruiting | University of Florence | 160 | 2025-04-01 | 2025-04-04 | |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment ICS-LABA, benralizumab, Placebo for Benralizumab - Eosinophilic Asthma | Phase 3 | Completed | AstraZeneca | 130 | 2025-03-28 | 2026-10-16 |
| Phase III Long-Term Extension Study With Dexpramipexole Dexpramipexole Dihydrochloride - Eosinophilic Asthma | Phase 3 | Terminated | Areteia Therapeutics | 509 | 2024-06-12 | 2025-12-15 |
| AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma AD17002, Placebo - Eosinophilic Asthma | Phase 1 / Phase 2 | Completed | Advagene Biopharma Co. Ltd. | 40 | 2023-11-27 | 2025-09-10 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 654 | 2023-03-27 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 1061 | 2023-01-30 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Active not recruiting | Areteia Therapeutics | 600 | 2023-01-30 | 2025-09-05 |
| Effect of Mepolizumab on Severe Eosinophilic Asthma Mepolizumab 100 MG - Asthma, Eosinophilic Asthma | Unknown | Hospital Clinico Universitario de Santiago | 30 | 2021-04-01 | 2023-09-25 | |
| Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma Observational - Eosinophilic Asthma | Completed | Mayo Clinic | 20 | 2021-02-16 | 2026-03-18 | |
| XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma XC8 100 mg, Placebo - Bronchial Asthma, Eosinophilic Asthma | Phase 2 | Completed | Chemlmmune Therapeutics LLC | 70 | 2020-12-16 | 2021-09-22 |
| Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma Autoantibody ELISA, Granulocyte Immunofluorescence - Churg-Strauss Syndrome, Eosinophilic Asthma | Completed | Queen Mary University of London | 120 | 2020-12-10 | 2025-01-30 | |
| Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma COPD Asthma, Eosinophilic Asthma | Unknown | Medical University of Warsaw | 36 | 2020-09-01 | 2022-05-31 | |
| Eosinophils Endotypes in Chronic Airway Inflammatory Diseases Eosinophilic Asthma, Chronic Sinusitis | Completed | University Hospital, Lille | 70 | 2020-03-03 | 2026-05-14 | |
| Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils no intervention - Eosinophilic Asthma, EGPA - Eosinophilic Granulomatosis With Polyangiitis | Recruiting | Medical University Innsbruck | 300 | 2020-02-26 | 2020-09-04 | |
| A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil Mepolizumab 100 MG [Nucala] - Eosinophilic Asthma | Phase 4 | Unknown | University of Sao Paulo General Hospital | 18 | 2020-01-09 | 2020-01-14 |
| Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma Dexpramipexole, Placebo - Eosinophilic Asthma, Asthma | Phase 2 | Completed | Knopp Biosciences | 534 | 2019-08-15 | 2023-04-13 |
Showing 20 of 29. Sign in to see all of them.
Pulmonary Eosinophilia (29) · Asthma (15) · Churg-Strauss Syndrome (4) · Hypereosinophilic Syndrome (2) · Disease (1) · Eosinophilia (1) · Eosinophilic Esophagitis (1) · Pulmonary Disease, Chronic Obstructive (1)
Hematologic Diseases (29) · Hemic and Lymphatic Diseases (29) · Leukocyte Disorders (29) · Lung Diseases (29) · Respiratory Tract Diseases (29) · Eosinophilia (28) · Hypereosinophilic Syndrome (27) · Immune System Diseases (18) · Hypersensitivity (16) · Hypersensitivity, Immediate (16) · Bronchial Diseases (15) · Lung Diseases, Obstructive (15) · Respiratory Hypersensitivity (15) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (4) · Autoimmune Diseases (4)
Antibodies, Monoclonal, Humanized (5) · reslizumab (5) · mepolizumab (4) · benralizumab (2) · heat-labile enterotoxin, E coli (2) · Dexpramipexole (1) · Injections (1) · Omalizumab (1) · Watchful Waiting (1) · histamine glutarimide (1)
Teva Branded Pharmaceutical Products R&D, Inc. (5) · Areteia Therapeutics (4) · Advagene Biopharma Co. Ltd. (2) · AnaptysBio, Inc. (1) · AstraZeneca (1) · Azienda Ospedaliero Universitaria di Cagliari (1) · Chemlmmune Therapeutics LLC (1) · Endeavor Health (1) · Hospital Clinico Universitario de Santiago (1) · Knopp Biosciences (1) · Kymera Therapeutics, Inc. (1) · Laval University (1) · Mayo Clinic (1) · Medical University Innsbruck (1) · Medical University of Warsaw (1)
United States (15) · Argentina (8) · Brazil (8) · Poland (8) · United Kingdom (8) · Canada (7) · Mexico (7) · South Korea (7) · France (6) · Romania (6) · Taiwan (6) · Ukraine (6) · Germany (5) · Israel (5) · South Africa (5)
Bruce Randazzo, MD (1) · Giselle Mosnaim, MD, MS (1) · Han-Pin Kuo, MD. Ph.D. (1) · Louis-Philippe Boulet, MD (1) · Michael E. Wechsler, MD (1) · Mona Bafadhel, MD (1) · Myles J Lewis, MD PhD FRCP (1) · Paul Pfeffer, MD (1) · Peter Wark, MBBS/PhD (1) · Rodrigo A Athanazio, MD, PhD (1)
PMID 39393433, PMID 25736990, PMID 28159511, PMID 30193936, PMID 30346831, PMID 30964365, PMID 31262379, PMID 31626990, PMID 27018175, PMID 27056586, PMID 37334358
2017 (1), 2023 (1)